Abstract Details

Title Clinical and Instrumental Findings and Disability Progression in Primary Progressive and Progressive Relapsing Multiple Sclerosis: A Comparison Study of a Sicilian Group of Patients

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 139

Objective

Background BACKGROUND: Relapsing-Remitting MS and PPMS have different prognosis. Immunomodulators and Immunosuppressors Disease Modifiymg Drugs (IMDMD/ISDMD) act on relapses but not on progression. Scanty studies indicate a similar progression rate in PPMS/PRMS.

Design/Methods DESIGN/METHODS: PPMS and PRMS patients were identified in an MS database established in 1990. End of follow-up was September 30, 2012. Continuous variables were compared by "Student t test", categorical variables with "chi square test", survival analyses by Kaplan-Meier estimates, and Cox regression models.

Results RESULTS: In a database including 1300 MS patients, we identified 134 affected by PPMS/PRMS. Thirty-four were excluded. Of the remaining 100 patients, 60 were females. Median age at onset was 38 years (range 7-62); median follow-up time 15 years (range 3-38). MS onset was monosymptomatic in 75% of patients; in 74% the pyramidal system was involved at onset. Six subjects died before we planned the study. Comparisons between the 55 PPMS and the 45 PRMS patients showed significant differences for median age at onset (40 yrs PPMS; 35 yrs PRMS; p = 0.02) and presence of infratentorial lesions at brain MRI (80% PPMS; 51% PRMS; p = 0.008). Time to reach EDSS 6.0 (median 8 years) or EDSS 7,0 (median 18 years) were similar for PPMS and PRMS also when we stratified by sex, type of onset, location of brain lesions at MRI, therapy for at least six months with IMDMD/ISDMD. Younger age at onset was associated with a longer time to reach EDSS 6.0 in PRMS group (14 vs. 8 yrs; p = 0.03).

Conclusions CONCLUSIONS: MS progression was similar in PPMS/PRMS and was unmodified by treatments. Younger age at onset was associated with slower progression in PRMS.

Authors/Disclosures
Giuseppe Salemi, MD (Istituto Di Neuropsichiatria) PRESENTER	No disclosure on file
Paolo Ragonese	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Lawrence J. Hirsch, MD, FAAN (Yale University Comprehensive Epilepsy Center)	Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceribell. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for marinus. The institution of Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rapport Therapeutics. Dr. Hirsch has received publishing royalties from a publication relating to health care. Dr. Hirsch has received publishing royalties from a publication relating to health care. Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker; Faculty for Fellows' training course with Neuropace. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Natus.
Maria Antonietta Mazzola, MD (Beth Israel Lahey Health)	Dr. Mazzola has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentec.
	No disclosure on file
Giovanni Savettieri, MD	No disclosure on file

��ɫ��

��ɫ��